Beijing Aosaikang Pharmaceutical Co., Ltd.

Equities

002755

CNE100001X92

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
9.8 CNY +0.41% Intraday chart for Beijing Aosaikang Pharmaceutical Co., Ltd. +14.75% -9.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection MT
Aosaikang Pharmaceutical Registers Breast Cancer Drug MT
Aosaikang Pharmaceutical's Unit Gets Nod for Two Drugs MT
Aosaikang Pharmaceutical's Unit Gets Nod to Trial ASKC202 Tablets MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Aosaikang Pharmaceutical's Unit Gets Nod to Test Gastric Cancer Drug MT
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) added to S&P Global BMI Index CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aosaikang Pharma's Unit Gets Nod to Amend Instructions for Heart Drug MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aosaikang Pharma Unit Registers Acid Reflux Drug in China MT
Aosaikang Pharma Registers Three Drugs MT
Aosaikang Pharma US Unit Gets Regulatory Nod For Anti-Tumor Drug Trial MT
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) dropped from S&P Global BMI Index CI
Aosaikang Pharma Wins Nod to Market Variant of Pfizer’s Breast Cancer Drug MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on June 20, 2022 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Beijing Aosaikang Pharmaceutical Co., Ltd. cancelled the acquisition of Jiangsu Vedkang Medical Science and Technology Co., Ltd. from Changzhou Beiruishi Enterprise Management Co., Ltd., Changzhou Yisiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin. CI
Propella Therapeutics, Inc. Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. for Development and Commercial Rights to CGS-200-5 in Greater China CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Directorate Appointments CI
Chart Beijing Aosaikang Pharmaceutical Co., Ltd.
More charts
BEIJING AOSAIKANG PHARMACEUTICAL CO., LTD., formerly Beijing New Oriental Star Petrochemical Engineering Co., Ltd., is a China-based company mainly engaged in pharmaceutical manufacturing business. The Company produces proton pump inhibitor injections through its subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002755 Stock
  4. News Beijing Aosaikang Pharmaceutical Co., Ltd.
  5. Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection